[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-455768-105":59,"doc-detail-455768-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","predictors-of-disease-progression-among-patients-in-the-thai-national-prion-disease-surveillance-program-poster-presentation","Predictors of Disease Progression Among Patients in The Thai National Prion Disease Surveillance Program - Poster Presentation","","The unfavorable prognosis of prion diseases underscores the need for a robust diagnostic approach to distinguish them from other causes of dementia, while biomarker correlation supports therapeutic development and clinical trial patient selection. A prospective Thai multicenter enrollment (March 2023–December 2024) collected clinical, demographic, exposure, and laboratory data including blood/CSF, brain MRI, and EEG. CSF RT-QuIC (SIMOA™ NfL/GFAP; ELISA tau) and MRC prion rating were used to compare sporadic CJD with non-prion disorders. Higher CSF tau and NfL aligned with worse baseline MRC scores and a main effect on progression, without significant biomarker-time interactions.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/predictors-of-disease-progression-among-patients-in-the-thai-national-prion-disease-surveillance-program-poster-presentation/455768/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/predictors-of-disease-progression-among-patients-in-the-thai-national-prion-disease-surveillance-program-poster-presentation/455768.png","ImageObject",300,407,{"name":92,"@type":93},"Rhys","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main goal of this study?","Question",{"text":112,"@type":113},"To identify predictors of disease progression among patients in the Thai national prion disease surveillance program and to evaluate biomarker correlations with clinical worsening.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were biomarkers and disease progression measured?",{"text":117,"@type":113},"CSF RT-QuIC was performed in all cases; NfL and GFAP were measured with the SIMOA™ assay, and tau was measured by ELISA. Disease progression used the MRC Prion Disease Rating Scale, with interactions assessed via linear mixed-effect models.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the results show about CSF biomarkers over time?",{"text":121,"@type":113},"CSF tau and NfL showed a significant main effect on MRC score, indicating worse baseline functional status with higher levels, but linear mixed-effects models found no significant interactions between CSF biomarkers and time to MRC score.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},455768,1790792328,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":19,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":52,"preview_page_count":4},687207024643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","DOI: 10. 1002/alz70856_104662  \nBIOMARKERS  \nPOSTER PRESENTATION  \nBIOMARKERS (NON-NEUROIMAGING)  \nPredictors of Disease Progression Among Patients in The Thai National Prion Disease Surveillance Program  \nChayanis Yolsiriwat1  Adipa Chongsuksantikul2  Prawit Oangkhana3   \nWatayuth Luechaipanit2  Thanaporn Haethaisong3  AbhinbhenWasontiwong Saraya2, 4  Poosanu Thanapornsangsuth4, 5, 6  \n1 King Chulalongkorn Memorial Hospital, Bangkok, Bangkok, Thailand  \n2Thai Red Cross Emerging Infectious Diseases Health Science Centre, King Chulalongkorn Memorial Hospital, Bangkok, Thailand  \n3Thai Red Cross Emerging Infectious Diseases Health Science Centre, King Chulalongkorn Memorial Hospital, The Thai Red Cross Society, Bangkok, Thailand  \n4 King Chulalongkorn Memorial Hospital, Bangkok, Thailand  \n5Thai Red Cross Emerging Infectious Diseases Health Science Centre, World Health Organization Collaborating Centre for Research and Training on Viral Zoonoses, King Chulalongkorn Memorial Hospital, The Thai Red Cross Society, Bangkok, Thailand  \n6 Memory Clinic, King Chulalongkorn Memorial Hospital, The Thai Red Cross Society, Bangkok, Thailand  \nCorrespondence  \nChayanisYolsiriwat, King Chulalongkorn Memorial Hospital, Bangkok, Bangkok, Thailand.  \n[Email:](Email: cc.yolsiriwat@gmail.com)[ cc.yolsiriwat@gmail.com](Email: cc.yolsiriwat@gmail.com)  \nAbstract  \nBackground: The unfavorable prognosis of prion diseases highlights the need fora robust diagnostic approach system to accurately distinguish them from other etiologies of dementia. Correlating biomarkers is crucial for advancing therapies and optimizing patient selection in clinical trials.  \nMethod: We prospectively enrolled participants with suspected prion disease from hospitals across Thailand from March 2023 to December 2024. Standardized questionnaires were developed to collect clinical and demographic data, diseasespecific exposures, and laboratory findings, including blood and CSF tests, brain MRI, and EEG. CSF RT-QuIC was performed in all cases, with NfL and GFAP measured using the SIMOA™ assay (Quanterix) and tau levels determined via ELISA (EUROIMMUN). Disease progression is monitored using the MRC Prion Disease Rating Scale. Baseline characteristics and investigational biomarkers were compared between sporadic CJD and non-prion disorders. Linear mixed-effect models were used to evaluated interactions between each biomarker and time, as these interactions directly represent disease progression. Predictive biomarkers were dichotomized using median levels as cut-offs to enable clearer group comparisons.  \nResult: Among 31 patients, 42% were female with mean age of 67 years. The most common clinical presentation is rapidly progressive dementia (84%) followed by pyramidal weakness, myoclonus and cerebellar dysfunction. There are no significant differences between core clinical features between both groups. CSF RT-QuIC was tested positive in almost all sporadic CJD and non in non-prion disorders. CSF tau is higher in sporadic CJD (4,027 pg/mL vs 377 ng/mL, p-value\u003C0.001). (Table 1) Sporadic CJD diagnosis and higher levels of CSF tau and CSF NfL reported a worse MRC score at baseline. (Figure 2A-C) Linear mixed-effects models revealed no significant interactions between CSF biomarkers and time to MRC score. (Table 2)  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2025 The Alzheimer’s Association. Alzheimer’s & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer’s Association.  \nAlzheimer’s Dement. 2025;21(Suppl. 2):e104662.  \n[https://doi.org/10.1002/alz70856_104662](https://doi.org/10.1002/alz70856_104662)  \nwi[leyonlinelibrary.com/journal/alz](leyonlinelibrary.com/journal/alz)  \n1of4  \nConclusion: Our study demonstrates a significant main effect of CSF tau and NfL on the MRC score but no interaction effects. ","cbCaitdZIhUynCZR","https://ap.wps.com/l/cbCaitdZIhUynCZR","pdf",1752935,"English","# Abstract\n## Background\n## Method\n## Result\n## Conclusion","[{\"question\":\"What was the main goal of this study?\",\"answer\":\"To identify predictors of disease progression among patients in the Thai national prion disease surveillance program and to evaluate biomarker correlations with clinical worsening.\"},{\"question\":\"How were biomarkers and disease progression measured?\",\"answer\":\"CSF RT-QuIC was performed in all cases; NfL and GFAP were measured with the SIMOA™ assay, and tau was measured by ELISA. Disease progression used the MRC Prion Disease Rating Scale, with interactions assessed via linear mixed-effect models.\"},{\"question\":\"What did the results show about CSF biomarkers over time?\",\"answer\":\"CSF tau and NfL showed a significant main effect on MRC score, indicating worse baseline functional status with higher levels, but linear mixed-effects models found no significant interactions between CSF biomarkers and time to MRC score.\"}]","Predictors of Disease Progression Among Patients in The Thai National Prion Disease Surveillance Program - Poster Presentation | PDF",1790744287]